Benzinga | Jul 16, 2021 08:37AM EDT

Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $107

Morgan Stanley analyst Matthew Harrison maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Equal-Weight and raises the price target from $69 to $107.